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Abstract Lactoferricin B (LfcinB) is a 25-residue antimicrobial
peptide released from bovine lactoferrin upon pepsin digestion.
The antimicrobial center of LfcinB consists of six residues
(RRWQWR-NH2), and it possesses similar bactericidal activity
to LfcinB. The structure of the six-residue peptide bound to
sodium dodecyl sulfate (SDS) micelles has been determined by
NMR spectroscopy and molecular dynamics refinement. The
peptide adopts a well defined amphipathic structure when bound
to SDS micelles with the Trp sidechains separated from the Arg
residues. Additional evidence demonstrates that the peptide is
oriented in the micelle such that the Trp residues are more deeply
buried in the micelle than the Arg and Gln residues.
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1. Introduction
Lactoferricin B (LfcinB) is a 25-residue peptide fragment
released from the N-terminal domain of bovine lactoferrin
(residues 17^41) upon pepsin digestion [1,2]. It has been
shown to be responsible for the majority of the antimicrobial
activity of lactoferrin. Lactoferricin B has antimicrobial activ-
ity against both Gram-positive and Gram-negative bacteria as
well as yeast [3]. In addition it has been shown to inhibit
tumor metastasis in mice [4]. Peptide fragments of lactoferrin,
including lactoferricin B, have been isolated from mice fed
lactoferrin-enriched milk [5]. Such evidence supports the hy-
pothesis that lactoferrin in milk is naturally digested in the
gastrointestinal tract to form antimicrobial peptides, protect-
ing infants as their immune system develops [6].
Studies on an 11-residue fragment of LfcinB (RRWQWR-
MKKLG) showed that it possesses antimicrobial activity sim-
ilar to the intact peptide, with reduced hemolytic activity com-
pared to LfcinB. In addition, the authors demonstrated that
both the hydrophobic and basic residues were necessary for its
antimicrobial activity [7]. Residues 4^9 (RRWQWR) of the
lactoferricin peptide (LfcinB4ÿ9) have been termed the antimi-
crobial center of lactoferricin B and when the C-terminal car-
boxyl group is amidated the hexapeptide has been shown to
display antimicrobial activity which compares favorably to
LfcinB [8]. Studies with Bacillus subtilis, Escherichia coli and
Staphylococcus aureus indicate that the 11-residue peptide and
the amidated six-residue peptide have the same minimum in-
hibitory concentration (MIC) as intact lactoferricin B [7,8].
Moreover, recent spectroscopic studies show that LfcinB
and its hexapeptide cause similar membrane disturbances in
model membranes suggesting that they have a similar mecha-
nism of action (personal communication, Dr. R. Epand,
Hamilton, Ont.).
While we have reported the NMR solution structure of the
25-residue lactoferricin B peptide [9], a structure of the pep-
tide in a membrane-like environment has yet to be deter-
mined. The elucidation of the structures of membrane pro-
teins by solution NMR spectroscopy methods is possible
using SDS micelles [10,11]. We have found that the intact
lactoferricin B peptide gives very broad resonances when
bound to SDS as well as DPC micelles (unpublished observa-
tions), hindering the elucidation of its micelle-bound struc-
ture. In this report we describe the structure of the antimicro-
bial center of the lactoferricin B peptide when bound to SDS
micelles, as determined by NMR spectroscopy.
2. Materials and methods
2.1. Materials
The amidated lactoferricin B peptide fragment (residues 4^9 of
LfcinB) was synthesized at the Peptide Synthesis Facility at Queen’s
University (Kingston, Ont.) and was puri¢ed by RP-HPLC at the
Peptide Synthesis Facility at the University of Calgary. The sodium
dodecyl-d25 sulfate (SDS-d25) and D2O were obtained from Cam-
bridge Isotopes Laboratories (Andover, MA), all other reagents
were obtained from Sigma (St. Louis, MO).
2.2. Circular dichroism (CD) spectroscopy
The peptide concentration for CD was 10 WM, in a 10 mM Tris
bu¡er, pH 7.2. In micellar samples 35 mM SDS was used, well above
the critical micelle concentration. The CD spectra were acquired in a
cylindrical cuvette with a 1 mm path length with a Jasco J-175 CD
spectrophotometer. The spectra were measured from 255 nm to 185
nm, with a 0.2-nm step resolution at 50 nm/min, a 2-s response time,
and a 1-nm bandwidth. Eight scans were collected and averaged with
the bu¡er baseline spectra subtracted.
2.3. NMR spectroscopy
The ¢nal peptide concentration was 4 or 10 mM in 90% H2O/10%
D2O, containing 250 mM perdeuterated SDS, pH 4.8. DSS was added
as an internal chemical shift reference compound. Two-dimensional
proton NMR spectra were acquired at 500 MHz on a Bruker
AMX500 spectrometer at 298 K. The number of data points in the
F2 and F1 dimension were 2048 and 512 respectively, with a spectral
width of 6024 Hz. The spectra were zero ¢lled to 2KU1K. The data
were processed on a Silicon Graphics Indy using NMRPIPE [12].
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TOCSY [13] spectra were acquired with a mixing time of 60 ms.
NOESY [14] spectra was acquired with mixing times of 50, 100 and
200 ms to check for spin di¡usion. The 100-ms mixing time NOESY
was used for the assignment and compilation of NOEs. Water sup-
pression was achieved using low power presaturation during the re-
laxation delay with additional gradient suppression in the NOESY
spectra. Hydrogen bonding was monitored via an amide exchange
experiment by dissolving a lyophilized NMR sample in 99.9% D2O
and immediately obtaining one-dimensional 1H NMR spectra at dif-
ferent time intervals.
Distance restraints for structural calculations were determined from
the peak volumes in the NOESY spectrum using NMRVIEW 3.1. The
restraints were classi¢ed as strong, medium or weak, using an internal
reference in the peptide. These restraints corresponded to distances of
2.7, 3.5 and 5.0 Aî respectively. For atoms where the methyl or meth-
ylene protons could not be stereospeci¢cally assigned a pseudoatom
correction was used [15].
Samples for NMR experiments in the presence of spin-labeled stea-
ric acid contained the same concentrations as described above. 5-
Doxyl stearic acid was added from a 0.1 M stock solution in deuter-
ated methanol to provide a ¢nal ratio of SDS to spin-labeled stearic
acid of 60:1 [16]. A TOCSY spectrum was obtained using the same
conditions as mentioned above.
X-Plor v3.851 [17] was used for all structure calculations according
to the protocol previously described [9]. Distance restraints were used
to obtain 97 structures calculated using restrained simulated annealing
molecular dynamics from an extended starting structure. Of the 97
structures generated, the 14 with the lowest energy were retained.
3. Results and discussion
The CD spectrum of LfcinB4ÿ9 (Fig. 1) changes signi¢-
cantly upon addition of SDS with the maximum at 195 nm
and the minimum at 205 nm becoming more prominent. In
addition, a minor negative peak at 225 nm appears upon the
addition of SDS. These three extrema most likely represent
the indole transitions of the two tryptophan residues [18], as
this spectrum is not indicative of a known protein secondary
structure. This increase in the absolute values of mean residue
ellipticity may be due to fewer conformers in solution and the
stabilization of the structure in the micellar environment.
The proton resonance assignments of LfcinB4ÿ9 in SDS
micelles were determined using the method of Wuºthrich [15].
There was no di¡erence in chemical shifts or NOE crosspeaks
between the 4- and 10-mM peptide NMR samples hence the
10-mM sample was used for assignment of residues. The pro-
ton chemical shifts are presented in Table 1. Many of the
chemical shifts observed deviated signi¢cantly from expected
random coil values. It is known that aromatic residues will
cause up¢eld ring current shifts when spins are above or be-
low the ring plane and down¢eld when the spins are in the
ring plane [15]. The chemical shifts of virtually all of the
residues were shifted up¢eld compared to the random coil
chemical shifts. The only residue that was not signi¢cantly
a¡ected was Arg-1. The most dramatic shifts were seen for
the amide protons of residue 2, 3, 4 and 6, all of which were
directly above or below one of the two Trp residues as deter-
mined by the structure described below. The K protons of
residues 3, 4 and 5 were the least a¡ected, as these were gen-
erally on the side of the molecule opposite from the indole
rings.
A total of 86 NOE crosspeaks were compiled from the 2D
NOESY spectrum (Fig. 2) as distance restraints in the struc-
ture calculations. Of the 86 distance restraints, 10 were me-
dium range, 44 sequential and 32 intra-residue. Intra-residue
restraints that would not a¡ect the structure calculations were
excluded. No hydrogen bonds were found based on the 1D 1H
NMR spectroscopy amide exchange experiment. No distance
violations larger than 0.3 Aî were observed in the ¢nal struc-
tures, suggesting that a unique structure is formed upon bind-
ing to the micelle. The 14 ¢nal structures with the lowest
energy had an RMSD of 0.947 Aî for heavy atoms and
0.265 Aî for backbone atoms when all residues were ¢tted
(Fig. 3). There were very few distance restraints obtained
for the N-terminal arginine due to chemical shift overlap
with other residues. When only residues 2^5 were superim-
posed the RMSD values were 0.544 Aî and 0.082 Aî for the
heavy and backbone atoms respectively.
The structures obtained did not appear to contain any reg-
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Fig. 1. CD spectra (deg.cm2/dmol) of 10 WM LfcinB4ÿ9 in 10 mM
Tris pH 7.4, in the presence (solid line) and absence (dotted line) of
1% SDS.
Fig. 2. Fingerprint region of the NOESY spectrum for 10 mM
LfcinB4ÿ9 in 90% H2O/10% D2O, 250 mM SDS, pH 4.8, at 298 K
and a mixing time of 100 ms. The amide resonances of residues 2^6
are labeled, as well as the amide protons of the amidated C-terminal
carboxyl group.
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ular backbone secondary structure. This agrees with both the
CD data and the amide exchange experiment. It would be
unexpected for a peptide of only six residues to contain a
regular secondary structure. The NOE connectivity pattern
appears to suggest a half turn for residues 3^6 [15], this is
probably coincidental and does not describe a stabilized sec-
ondary structure. Although LfcinB4ÿ9 does not contain a con-
ventional secondary structure it is not a random coil. The
micelle-bound peptide forms a well-de¢ned structure, where
the peptide adopts a conformation to obtain the best separa-
tion of the hydrophobic and basic residues. In aqueous sol-
ution the LfcinB4ÿ9 peptide is unstructured as judged from the
chemical shifts and the absence of NOE crosspeaks between
any of the sidechains in NMR spectra (data not shown).
While there was no well-de¢ned structure for the peptide
free in solution, it acquires a unique structure when bound to
the SDS micelle. The peptide formed an amphipathic struc-
ture with the three Arg residues on one side of the structure
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Fig. 3. Final 14 lowest energy structures of LfcinB4ÿ9 obtained in SDS-d25 micelles with residues 2^5 ¢tted to the mean structure. A: Backbone
of LfcinB4ÿ9. B: Side view with Gln pointing out of the page. C: Bottom view of all of the side chains of LfcinB4ÿ9. The Trp residues are in
black, the Gln residue in dark gray and Arg residues in light gray. Residues are numbered 1^6. The RMSD for backbone atoms is 0.082 Aî
and 0.544 Aî for heavy atoms. The ¢gures were generated using INSIGHTII (Biosym, San Diego, CA).
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and the two Trp residues on the other with the Gln centrally
located (Figs. 3 and 4). The formation of an amphipathic
structure has been postulated to be a requirement for cationic
antimicrobial peptides (recent reviews by [19,20]), and has
been observed for helical peptides like cecropin A [21] and
magainin 2 [22] and L-sheet peptides such as insect defensin
A [23].
The structure of the 25-residue LfcinB peptide in solution
was determined to have an amphipathic structure with the
Trp residues separated from the positively charged Arg and
Lys residues [9]. While the structure of the micelle-bound
hexapeptide, LfcinB4ÿ9, is also amphipathic, the two struc-
tures can not be superimposed. This is due to the fact that
the sidechains of the C-terminal L-sheet of LfcinB interact
with the sidechains of the N-terminal L-sheet, speci¢cally
Ile-18 intercalates between Trp-6 and Trp-8 [9], disrupting
the indole interactions which are clearly evident in LfcinB4ÿ9.
A TOCSY spectrum of LfcinB4ÿ9 in SDS micelles in the
presence of 5-doxyl stearic acid was used to study the orien-
tation of the peptide in the micelle [16]. All of the resonances
in the TOCSY spectrum were a¡ected by the presence of the
spin label in the micelle (data not shown), however the Trp
peaks were broadened the most, followed by Arg, and the Gln
resonances were the least a¡ected. This agrees with the struc-
ture that was determined for LfcinB4ÿ9 where the two Trp
residues are more deeply buried in the micelle with the Arg
and Gln sidechains more solvent-exposed.
The structural stability of LfcinB4ÿ9 in the SDS micelles
appears to be due to the anchoring nature of many of the
residues in the peptide. The three Arg residue sidechains
and the N-terminus probably interact electrostatically with
the negatively charged head groups of the SDS molecules.
Tryptophan is known to position peptides at the membrane
interface [24] such that they act as membrane anchors [25].
The two Trp residues of LfcinB4ÿ9 reside within the micelle
and may act as hydrophobic anchors. This provides the six-
residue antimicrobial center of lactoferricin with ¢ve residues
which will act to position the peptide at the bilayer surface,
therefore it is perhaps not surprising to ¢nd that such a small
peptide will form a stable folded structure in micelles.
Yau et al. recently demonstrated that Trp analogues will
bind in the interface of POPC bilayers, residing amongst the
acyl chain carbons closest to glycerol [26]. This con¢rms pre-
vious data which suggested that Trp residues [27] and indole
[28] both have a preference for the hydrocarbon-water inter-
face of membranes. The importance of tryptophan as a mem-
brane interface binding moiety has been observed for various
peptides such as gramicidin A [29], galanin [16] and mellitin
[30]. There is a tryptophan-rich class of antimicrobial peptides
including indolicidin [31] and tritrpticin [32], suggesting that
tryptophan may play a pivotal role in membrane binding. In
addition Trp- and Arg-rich hexamer peptides were identi¢ed
using combinatorial chemistry which had similar antimicro-
bial activities to magainin 2 and cecropin [33]. While the in-
tact 25-residue lactoferricin B peptide would not be included
in such a class, the LfcinB4ÿ9 peptide studied here should be
considered a tryptophan-rich peptide, as this amino acid con-
stitutes one-third of the residues.
While the structure of the peptide and its orientation in a
micelle have been determined from this work, the mechanism
of its bactericidal activity remains to be investigated. Various
lytic mechanisms have been proposed for amphipathic K-hel-
ical antimicrobial peptides (for recent reviews see [34,35]).
Since LfcinB4ÿ9 has an amphipathic structure it is possible
that it has a related mechanism. The proposed lytic mecha-
nisms for antimicrobial peptides include the channel forming
models proposed for magainin, cecropin and almethicin [35].
The formation of bundles of amphipathic molecules that form
a pore with a hydrophilic surface is doubtful for LfcinB4ÿ9
due to its short length. It has also been suggested that small
peptides may still form bundles by forming head-to-tail struc-
tures [36], this is also unlikely since there are no electrostatic
or hydrophobic interactions to stabilize such a structure. An-
other possible mechanism is the induction of monolayer cur-
vature strain by amphipathic peptides [34,37]. It is probable
that LfcinB4ÿ9 is inducing membrane curvature strain such as
the model lytic peptide 18L [38] and as has been recently
suggested for magainin 2 [39].
In conclusion, LfcinB4ÿ9 has been found to form a stable
amphipathic structure in SDS micelles, with the Trp side-
chains located deeper in the micelle than the Arg and Gln
residues. The stable structure appears to be due to the mem-
brane anchoring properties of the Trp and Arg residues. Fur-
ther work must be performed to elucidate the structure of the
25-residue peptide in a membrane mimicking environment
and to determine the lytic mechanism of these two forms of
lactoferricin B.
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Table 1
Proton chemical shifts (ppm) relative to DSS for LfB4ÿ9 in the pres-
ence of 250 mM SDS-d25 at 298 K and pH 4.8
NH KH LH QH Others
Arg-1 4.01 1.74, 1.94 1.66 NH: 3.17
OH: 6.88
Arg-2 7.55 4.08 1.53, 1.57 1.22, 1.36 NH: 2.93
OH: 7.18
Trp-3 7.54 4.70 3.05, 3.13 1H: 9.73 2H: 7.16
4H: 7.54 5H: 7.00
6H: 7.06 7H: 7.41
Gln-4 7.82 4.33 1.85, 2.00 2.19 NH: 6.72, 7.40
Trp-5 7.89 4.54 3.26 1H: 9.83 2H: 7.24
4H: 7.62 5H: 7.02
6H: 7.05 7H: 7.39
Arg-6 7.76 4.02 1.58, 1.73 1.24 NH: 2.99
OH: 6.91
CONH2 NHe : 6.64
NHz : 6.84
Fig. 4. Bottom view of a van der Waals surface plot of LfcinB4ÿ9
in SDS-d25 micelles. The Trp residues are in black, the Gln residue
in dark gray and the three Arg residues in light gray. This ¢gure
was generated using INSIGHTII (Biosym, San Diego, CA).
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